US2010261729A1PendingUtilityA1

Methods for the treatment of erectile dysfunction using fispemifene

Assignee: QUATRX PHARMACEUTICALS COMPANYPriority: Jun 13, 2007Filed: Jun 8, 2010Published: Oct 14, 2010
Est. expiryJun 13, 2027(~0.9 yrs left)· nominal 20-yr term from priority
A61P 15/00A61P 15/10A61K 9/00A61K 31/135A61K 31/075A61K 31/53A61K 31/496A61K 31/085A61K 31/4985A61K 31/519
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.

Claims

exact text as granted — not AI-modified
1 . A method of treating erectile dysfunction, comprising the step of administering an effective amount of fispemifene to a subject in need thereof. 
     
     
         2 . A method of treating erectile dysfunction, comprising the step of determining that the individual has low serum total testosterone, in a range of less than about 400 ng/dL, and administering fispemifene in an amount effective to increase serum testosterone. 
     
     
         3 . A method of treating erectile dysfunction in an individual insufficiently responsive to treatment with a PDE-5 inhibitor, comprising administering fispemifene to said individual in an amount effective to treat the erectile dysfunction. 
     
     
         4 . The method of  claim 3 , wherein said PDE-5 inhibitor is selected from the group consisting of: sildenafil, vardenafil, and tadalafil. 
     
     
         5 . The method of  claim 4 , wherein said PDE-5 inhibitor is tadalafil. 
     
     
         6 . The method of  claim 5 , wherein the effective amount is 2.5 mg or 5 mg. 
     
     
         7 . A method of treating erectile dysfunction in an individual having low testosterone and who is suffering from chronic obstructive pulmonary disease, HIV infection, or metabolic syndrome, comprising administering an effective amount of fispemifene to said individual. 
     
     
         8 . The method according to any one of  claims 1 ,  2 , 3  and  7 , wherein an effective amount of fispemifene is in a range of 10 mg to about 1000 mg. 
     
     
         9 . The method according to any one of  claims 1 - 7 , wherein fispemifene is administered as an oral formulation.

Join the waitlist — get patent alerts

Track US2010261729A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.